Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 13/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267971 | 1.00 | REN (0.42) | RENAXLMERTKRORC | |
| SCHEMBL13161210 | 0.95 | REN (0.45) | RENRORC | |
| SCHEMBL3267579 | 0.95 | REN (0.43) | REN | |
| SCHEMBL8435065 | 0.95 | REN (0.43) | REN | |
| SCHEMBL3277251 | 0.95 | REN (0.45) | RENRORC | |
| SCHEMBL8427630 | 0.94 | REN (0.43) | RENAXLMERTK | |
| SCHEMBL3272255 | 0.94 | REN (0.43) | RENAXLMERTK | |
| SCHEMBL13161133 | 0.94 | REN (0.43) | RENAXLMERTK | |
| SCHEMBL13161201 | 0.94 | REN (0.45) | RENRORC | |
| SCHEMBL3268169 | 0.94 | REN (0.45) | RENRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1987834-A2 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885AXL 3794/4885MERTK 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.